TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
December 23, 2013 (Issue: 1432)
Three tumor necrosis factor (TNF) inhibitors – infliximab
(Remicade), adalimumab (Humira), and certolizumab
pegol (Cimzia) – are approved by the FDA
for treatment of moderately to severely active Crohn’s
disease in adults who have had an...more
1. Drugs for inflammatory bowel disease. Treat Guidel Med Lett 2012; 10:19.
2. OH Nielsen and MA Ainsworth. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013; 369:754.
3. JF Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.
4. LY Lee et al. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24:1078.
5. JP Terdiman et al. American Gastroenterological Association Institute Guidelines on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013; 145:1459.
6. G Van Assche et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61:229.
7. S Schreiber et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239.
8. GR D'Haens et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.
9. V Pittet et al. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis 2013; 7:820.
10. E Louis et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142:63.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
Article code: 1432b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
